VCN-12 / Theriva Bio - LARVOL DELTA

Preclinical data for VCN-12 was presented at the ESGCT 32nd Annual Congress (GlobeNewswire) - "Data presented at ESGCT showed that VCN-12 provided increased cell killing compared to VCN-01 in a variety of cancer cell models in vitro and displayed higher levels of hyaluronidase activity. In animal studies, intravenous VCN-12 had a similar toxicity profile to VCN-01 in immunodeficient mice bearing human tumor xenografts....Additional preclinical studies to confirm these findings are ongoing."

Preclinical • Oncology

Theriva Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (GlobeNewswire) - "Co-founder of VCN Biosciences...will present new mechanistic and preclinical data for VCN-12, a next generation oncolytic adenovirus selected from Theriva’s VCN-X discovery program....In addition to the scheduled presentation on VCN-12, a recently-published pre-ESGCT meeting monograph details the results of a preclinical study conducted by investigators at the University of Navarra evaluating the intracranial administration of VCN-01 for the potential treatment of brain tumors."

Preclinical • Brain Cancer